What is Neuronoff?
Neuronoff is a pioneering medical technology firm focused on the development of the Injectrode Platform. This innovative solution addresses the limitations of traditional pain management by providing a minimally invasive alternative to pharmacological interventions and complex surgical procedures. The platform utilizes a needle-based delivery system to place a device that establishes a low-impedance path for electrical signals, effectively modulating pain pathways. By replacing repetitive drug injections with a targeted bioelectronic approach, Neuronoff is addressing a critical gap in the healthcare market for accessible, long-term pain relief solutions. The company's technology represents a paradigm shift in neuromodulation, emphasizing patient-centric design and procedural simplicity to improve clinical outcomes for those suffering from chronic conditions.
How much funding has Neuronoff raised?
Neuronoff has raised a total of $12.2M across 3 funding rounds:
Multiple Rounds
$12.2M
Grant (2025): $3.2M with participation from National Institutes of Health
Other Financing Round (2025): $4.5M, investors not publicly disclosed
Other Financing Round (2025): $4.5M, investors not publicly disclosed
Key Investors in Neuronoff
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical non-dilutive capital to support high-impact medical innovation.
Undisclosed Investor
An undisclosed institutional partner participating in the recent strategic financing round to support the advancement of neuromodulation technology.
Undisclosed Investor
An undisclosed institutional partner participating in the recent strategic financing round to support the advancement of neuromodulation technology.
What's next for Neuronoff?
With the infusion of this recent capital, Neuronoff is well-positioned to scale its clinical validation efforts and refine its manufacturing processes. The strategic focus will likely shift toward navigating regulatory pathways and expanding the reach of the Injectrode Platform within the broader pain management ecosystem. As the company transitions into a more mature operational phase, the emphasis will remain on demonstrating the long-term efficacy and safety of its device. Future growth will be driven by the integration of this technology into standard clinical workflows, potentially disrupting the multi-billion dollar pain management market by offering a sustainable, non-pharmacological alternative that reduces the burden on both patients and healthcare systems.
See full Neuronoff company page
